A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids.

Hum Reprod Open · 2019 · PMC6870550 · PMID 31777761

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

After discontinuation of asoprisnil treatment, the endometrium showed a trend of regression toward the pattern observed at baseline of the pivotal studies.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.